NEW YORK (GenomeWeb News) – Blueprint Medicines today announced a collaboration with Wellcome Trust Sanger Institute and the Massachusetts General Hospital Cancer Center to identify new cancer targets.

The partnership will use Sanger Institute's and Mass General's extensive human cancer cell line panel and BluePrint's next-generation, highly selective kinase inhibitor compounds. Cambridge, Mass.-based Blueprint is developing the kinase inhibitors for treating genetic abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.